Rayner appoints new VP Americas ahead of AAO 2024
Posted on 16/10/2024
Rayner, a global manufacturer of products for cataract surgery headquartered in Worthing, UK, announces the appointment of Scott Corning as Vice President, Americas.
Scott comes to Rayner with 25 years of experience developing and driving successful brands and commercial teams within the ophthalmic pharmaceutical and medical device industries. Notably, Scott served as Senior Vice President, Commercial at Ocular Therapeutix to contribute to company strategy and lead their commercial effort. Prior to that, Scott worked at Alcon in both the Surgical and Pharmaceutical Divisions. His breadth of experience will enable him to support Rayner’s continued focus on optimizing visual outcomes for surgeons and their patients across the United States, Canada and beyond.
This appointment comes during a particularly exciting year of growth and development for Rayner, as it celebrates the recent implantation of the new RayOne Galaxy IOL in the US. The world’s first spiral IOL was successfully implanted in the RayOne Galaxy IOL U.S. Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) Study. If successful, the results of the study are intended to allow a Pre-Market Approval (PMA) submission to the FDA.
Rayner’s portfolio also includes OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%, a product added to ophthalmic irrigating solutions to prevent intraoperative miosis, maintain pupil size, and reduce postoperative ocular pain. OMIDRIA® will be the subject of an exciting presentation at the upcoming AAO congress in Chicago, IL.
Scott explained: “I am delighted to have joined Rayner during such a remarkable time. I look forward to leading and developing our newly-formed, specialized teams so they may focus on the clinically-based sale of our products in both surgical devices and pharmaceuticals. Our ultimate goal is to improve patient outcomes through continued innovation.”
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
The RayOne Galaxy intraocular lens is currently under trial investigation and has not yet received FDA approval for commercial sale in the United States. Participation in the clinical study is subject to specific eligibility criteria, and potential risks associated with the device may apply.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2024 Rayner Group, all rights reserved. ‘Rayner’, ‘RayOne’, ‘Galaxy’ and ‘OMIDRIA’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners.
Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ | EC-2024-167 EN